Pancreatic cancer is on the rise in the United States, but there's another, less common type called pancreatic neuroendocrine ...

With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer ...

Jennifer Chan, MD, MPH, discussed the recent FDA approval of cabozantinib in pancreatic and extrapancreatic neuroendocrine ...

Cabozantinib significantly improved progression free survival in patients with pNET and epNET compared with placebo.

Neuroendocrine tumors that start in the pancreas tend to be more aggressive and have a poor prognosis.

The US Food and Drug Administration has approved cabozantinib (Cabometyx), an oral tyrosine kinase inhibitor, for patients with previously treated advanced neuroendocrine tumors.

The FDA approved cabozantinib for previously treated, unresectable, locally advanced or metastatic, well-differentiated ...